Effectivity comparison of amitriptyline versus gabapentin as neurophatic pain therapy in elderly with type ii diabetes mellitus by Jaya, Made Krisna Adi & Herawati, Fauna
  
 
 
    
 
 
                          
 
EFFECTIVITY COMPARISON OF AMITRIPTYLINE VERSUS GABAPENTIN AS NEUROPHATIC PAIN 
THERAPY IN ELDERLY WITH TYPE II DIABETES MELLITUS
*,1Made Krisna Adi Jaya
1Pharmacy Department, Institute of Health Sciences Medika Persada Bali (IIK Medika Persada Bali
2Department of Clinical Pharmacy, Pharmacy Faculty
ARTICLE INFO                                        ABSTRACT
 
 
Background:
system. The incidence of diabetic neuropathy was found more prevalent in elderly (44%) compared 
to adult (24%). Amitriptyline and Gabapentin are widely used on treatment o
There were variations in the results of the studies that have been done related to effectiveness 
between both drugs, causes the need further research, especially on geriatrics. 
Objective: 
Gabapentin for diabetic neuropathic pain in geriatric. 
Methods:
outcome targets were neuropathy pain scale reduction (
Whitney U, and Chi
Result:
compared to baseline. Comparison head to head at low doses, Amitriptyline showed reduce pain 
intensity greater than Gabapentin (p < 0.05), while on therapeutic doses show the
in efficacy between two drugs (p > 0.05). 
Conclusion:
to Gabapentin.
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INTRODUCTION 
 
Neuropathy in diabetes mellitus is a disorder that occurs in the 
peripheral nervous system. These disorders arise due to damage 
small blood vessels (microvascular) due to blood glucose levels 
are high. (Dyck et al., 2009; Fink and Oaklander
et al., 2015) Neuropathy in patients with diabetes, is a 
complication with the greatest incidence, which is 60
compared to other diabetic complications. The incidence of 
diabetic neuropathy was found more prevalent in elderly (44%) 
compared to adult (24%). (Lavery et al., 
Miller, 2008) Amitriptyline and Gabapentin are widely used on 
treatment of neuropathic pain. There were many variation 
effectivity research result between both drug as first line 
neurophatic pain, cause need further reaserch with hope the 
results can be used as a reference, especially in the local health 
authority to determine the best therapy of diabetic neuropathic 
pain on geriatrics. (Jefferies, 2010; Lacy et al
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 Neuropathy in diabetes mellitus is a disorder that occurs in the peripheral nervous 
The aim of this study was to compare the effectiveness of Amitriptyline versus 
 
 A prospective cohort study involving 70 elderly were observed during 4 weeks. The 
≥ 2 unit). Non
-Square test were used to analyze the outcome. 
 The whole subjects who got Amitriptyline or Gabapentin decreased pain scale 
 
 Amitriptyline was found better in reducing diabetic neuropathic pain intensity compared 
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, 2005; Javed 
-70% 
2004; Onge and 
., 2012) 
 
 
 
MATERIALS AND METHOD
 
Subjects 
 
The population of this study were
years with painful diabetic neuropathy who have a pain score 
at least 2 of Visual Analog Scale (VAS), Numeric Rating Scale 
(NRS), or Verbal Rating Scale (VRS). Patients were 
undergoing outpatient in polyclinic nervous, endocrin
interna at Sanglah General Hospital Center in Denpasar
who received Amitriptyline or Gabapentin therapy. Samples 
are part of the population that met the inclusion criteria and 
there are no samples are included in the exclusion criteria. The 
inclusion criteria were defined: men and women aged 
years, patients with diabetes mellitus type 2 with blood sugar 
levels under control, patients with a diagnosis of painful 
diabetic neuropathy, patients who obtain pain therapy of 
diabetic neuropathy such as Amitriptyline or Gabapentin for 
the first time or who have history of both drugs and therapy 
has been stopped at least 5 half
drugs. The exclusion criteria were defined: patients were not 
willing to participate in the study; patients with a history of 
heart disease, kidney failure, and impaired liver function; 
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patient contraindications or allergy to Amitriptyline or 
Gabapentin.  Sampling was carried out after obtaining the 
approval of research ethics committee. Ethical clearance 
number was 185 / UN.14.2 / R & D / 2015 as well as delivery 
to the patient's informed consent. Patients will be involved in 
this study if they have understood and signed the informed 
consent that has been prepared by the researcher. This study 
used a non-experimental analytical methods, that is prospective 
cohort, where the study subjects were divided into two groups 
according to treatment obtained by the patients. 
 
Clinical Assesment 
 
Basic characteristics such as demographics, Body Mass Index 
(BMI), risk factors, lipid profile (total cholesterol, HDL, LDL, 
TG), the use of drug therapy with other diagnoses 
(antihypertension, antidyslipidemia, and neuroprotector 
therapy), polypharmacy and compliance recorded as a basic 
characteristic.  The methods of data collection is done by direct 
measurement technique in which researchers take 
measurements and recording of subjects with diabetic 
neuropathic pain. The data collection of Amitriptyline and 
Gabapentin effectiveness performed by asking the patient to 
fill the VAS, NRS, or VRS before it is treated as a baseline and 
4 weeks after treatment with Amitriptyline and Gabapentin as 
an end point measurement. (EMEA 2007) The sampling 
technique used is non-probability consecutive sampling where 
researchers will take all subjects who were diagnosed with 
diabetic neuropathy in accordance with the inclusion and 
exclusion criteria, up to the minimum number of subjects met. 
By using the formula robustness analysis in a cohort study, the 
minimum sample to be observed to represent the population in 
each group was 35 patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Outcomes 
 
The observed therapeutic effectiveness outcomes were 
reduction in diabetic neuropathy pain intensity at least 30-50% 
or reduction at least two units on VAS, NRS, or VRS as 
compared to baseline and comparison head to head between 
two drugs. (EMEA 2007) 
 
Statistical Analysis 
 
Statistical analysiswere performed to test the baseline 
characteristic and outcomes study. 
 
1. Baseline Characteristic Analysis 
 
Analysis of baseline characteristics comparison conducted by 
the Mann-Whitney U and Chi-Square test for abnormally 
distributed and Tow Independent Sample Pair T-Test for 
normally distributed data.  
 
2. Therapeutic Effectiveness Analysis 
 
Effectiveness between two drugs were analyzed by Wilcoxon 
Sign Rank Test for dependent sample and Maan Whitney U for 
independent sample. 
 
RESULTS 
 
Ninety one subjects were collected during 4 month period. 
There were 52 patients placed on Amitriptyline group and 39 
patients in the Gabapentin group. Twenty-one subjects were 
dropped out during the observation period, eventually 70 
subjects were observed until the final stages, which consisted 
of 35 patients in the group of Amitriptyline and 35 patients in 
the Gabapentin group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Subjects Baseline Characteristics 
 
Baseline Characteristics Amitriptyline Group (n = 35) Gabapentin Group (n = 35) p Value Analysis 
Age (Year) 62.11 ± 3.47 63.46 ± 4.90 0.709 MWU 
Gender 
Male [n (%)] 23 (65.71%) 22 (62.86%) 0.803 Chi-S 
Female (P) [n (%)] 12 (34.29%) 13 (37.14%) 
BMI (Kg/m2) 26.73 ± 3.71 26.15 ± 2.96 0.469 T-Test 
High (cm) 164 ± 6.67 162 ± 6.86 0.118 UMW 
Weight (Kg) 72 ± 10.69 68 ± 8.92 0.128 T-Test 
Risk Factor 
1. Smoking [n (%)] 7 (20%) 10 (28.57%) 0.403 Chi-S 
2. Hypertension [n (%)] 18 (51.43%) 24 (68.57%) 0.143 Chi-S 
SBP (mmHg) 135 ± 20.10 133 ± 16.72 0.845 MWU 
DBP (mmHg) 86 ± 9.00 83 ± 10.36 0.412 MWU 
3. Dyslipidemia [n (%)] 20 (57.14%) 21 (60%) 0.808 Chi-S 
Total Cholesterol (mg/dL) 163.83 ± 55.20 165.37 ± 46.97 0.810 MWU 
LDL (mg/dL) 96.20 ± 35.14 88.91 ± 29.92 0.385 MWU 
HDL (mg/dL) 42.91 ± 14.48  43.26 ± 12.81 0.604 MWU 
TG (mg/dL) 151.29 ± 95.17 147.31 ± 71.72 0.729 MWU 
Duration of Diabetes Mellitus (Year) 7.46 ± 4.02 8.74 ± 3.80 0.079 MWU 
Another Therapy 
1. Neuroprotector [n (%)] 25 (71.43%) 30 (71.43%) 0.145 Chi-S 
B complex Vitamin 10 (28.57%) 12 (34.28%) 
Mecobalamin 15 (42.86%) 18 (51.43%) 
2. Antihypertension Drug [n (%)] 18 (51.43%) 24 (68.57%) 0.143 Chi-S 
3. Antidiabetic Drug [n (%)] 35 (100%) 35 (100%) 1.000 Chi-S 
4. Antidyslipidemia Drug [n (%)] 20 (57.14%) 21 (60%) 0.808 Chi-S 
Baseline Pain Score 3.37 ± 1.06 3.14 ± 1.00 0.376 MWU 
Compliance (%) 90.67 ± 6.95 91.95 ± 5.83 0.332 MWU 
Polypharmacy (amount of drug) 4.69 ± 1.32 5.14 ± 1.09 0.110 MWU 
Glossary of terms: MWU = Mann Whitney U; T-Test = Tow Independent Sample T-Test Pair ; Chi-S = Chi-Square Analysis; SBP = Systolic Blood Pressure; 
DBP = Diastolic Blood Pressure ; LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein; TG = Triglyserid; B-Complex : Contains Vitamin B1, 
B6, and B12; Mecobalamin = Vitamin B12. 
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Table 2. Amitriptyline and Gabapentin Effectiveness as Therapy 
 
Reduction in Pain 
Intensity  (Unit) 
Amitriptyline Group (n 
= 35) [n (%)] 
p Value of Amitriptyline 
Group Compare to Baseline 
Gabapentin Group 
(n = 35) [n (%)] 
p Value of Gabapentin Group 
Compare to Baseline 
4 3 (8.57%) p = 0.0000 
Sig. 
1 (2.86%) p = 0.0000 
Sig. 3 19 (54.29%) 12 (34.29%) 
2 13 (37.14%) 22 (62.86%) 
              n = Number of Subjects; Sig = Significant (p < 0.05) 
 
Table 3. Results Comparison of Amitriptyline and Gabapentin at Sub Therapeutic Doses 
 
The Research Group 
Reduction in Pain Intensity [n (%)] 
p Value 
> 2 (Unit) 2 (Unit) 
Amitriptyline Group (< 25 mg/day)  
(n = 6) 
4 
(66.7%) 
2 
(33.3%) 
0.037 
Sig. 
Gabapentin Group (< 300 mg/day) 
 (n=19) 
4 
(21%) 
15 
(79%) 
                                                 n = Number of Subjects ; Sig = Significant (p < 0.05) 
 
Table 4. Results Comparison of Amitriptyline and Gabapentin at Usual Doses 
 
The Research Group 
Reduction in Pain Intensity [n (%)] 
p Value 
> 2 (Unit) 2 (Unit) 
Amitriptyline Group (25 mg/day)  
(n= 29) 
18 
(62%) 
11 
(38%) 
0.703 
NS 
Gabapentin Group (< 300 mg/day) 
(n=16) 
9 
(56.3%) 
7 
(43.8%) 
                                 n = Number of Subjects ; NS = Not Significant (p > 0.05) 
 
 
 
Figure 1. Flow Chart of Subjects Selection 
 
 
A total of 128 elderly patients were diagnosed with diabetic neuropathic pain in Sanglah Hospital during 
December 2015-March 2016 period. 
37 patients were excluded: 
• 22 patients only received a neuroprotective therapy (B-complex or Mecobalamin). 
• 9 patients received paracetamol 650 mg as pain therapy. 
• 3 patients had a history of heart disease (Stroke & ACS) 
• 2 patients received tramadol therapy. 
• 1 patient had a history of chronic kidney disease (CRF). 
91 subjects were fulfilled the criteria for inclusion and exclusion, that 52 people in the group of 
Amitriptyline and 39 people in the group of Gabapentin 
17 Patients were Droped Out: 
• 6 patients with adherence <80% 
• 5 patients did not regain control 
• 4 patients stopped taking the drug 
• 2 patients moved to other health services 
4 Patients Drop Out: 
• 2 patients with adherence <80% 
• 1 patient did not regain control 
• 1 patients stopped taking the drug 
35 patients in Amitriptyline group were 
successfully analyzed until the final stage 
35 patients in Gabapentin group were 
successfully analyzed until the final stage 
 
39 patients were followed for 4 weeks in the 
group of Gabapentin 
52 patients were followed for 4 weeks in the 
group of Amitriptyline 
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Subjects Characteristics 
 
The demographic characteristics of subjects in this study were 
determined by age, gender, body mass index, the risk factors, 
another therapeutic drugs, baseline pain score, adherence, and 
polypharmacy. The demographic characteristics of patients 
were found not significantly different between both groups (p 
> 0.05). The characteristics of patients are shown in Table 1. 
 
Effectivity comparison between amitriptyline versus 
gabapentin 
 
The results of measuring the effectiveness between 
Amitriptyline Vs Gabapentin for the treatment of diabetic 
neuropathic pain in geriatrics, showed that both drugs can 
reduce pain scale score ≥ 2 units compare to baseline with the 
p value < 0.05 (Table 2). The drugs administration doses in 
this study were varied, so that the necessary test head to head 
between Amitriptyline and Gabapentin at sub therapeutic doses 
(low dose) and the usual dose (therapeutic dose). Low dose 
group Amitriptyline is < 25 mg / day whereas Gabapentin < 
300 mg / day. Amitriptyline usual dose is 25 mg / day whereas 
Gabapentin is 300 mg / day. Comparisons head to head 
between two drugs are shown in Table 3 and Table 4. 
 
DISCUSSION 
 
The therapeutic dose recommended guidelines in the treatment 
of diabetic neuropathic pain for Amitriptyline was started at a 
dose of 10-25 mg / day followed by a maintenance dose of 25-
100 mg / day, whereas Gabapentin begins with a dose of 100-
300 mg / day followed by a maintenance dose of 300- 1200 mg 
/ day according to the severity of pain experienced by the 
patient. (Moulin et al., 2014; Aslam et al., 2014; Attal et al., 
2010; Bansal et al., 2006) In this study Amitriptyline and 
Gabapentin proved effective in reducing diabetic neuropathic 
pain significantly compared with baseline (p < 0.05). 
Comparison head to head at the usual dose between two drugs 
showed there was no difference effectivity (p > 0.05) with the 
value of Number Need to Treat (NNT) is 18. Comparison on 
sub therapeutic doses showed a different results, which 
Amitriptyline can reduce pain intensity significantly greater (p 
< 0.05) when compared Gabapentin with NNT values equal to 
3. The results obtained in this study are in accordance with a 
systematic study and meta-analysis showed that the 
Amitriptyline had NNT value better than Gabapentin, where 
the value of NNT Amitriptyline is in the interval 1.3-1.5, while 
NNT for Gabapentin were in the interval from 5.8 to 6.6. 
(Javed et al., 2015; Moulin et al., 2014; Backonja et al., 1998)
Amitriptyline was allegedly working reduce pain intensity by 
modulating the transmission of serotonin and norepinephrine 
(NE), which will impact on the activity of inhibiting the 
reuptake of serotonin (5-HT) and norepinephrine by 
presynaptic receptor. Increased concentrations of these 
neurotransmitters in the synaptic cleft cause a decrease in the 
number of adrenaline receptor beta which will have an impact 
on pain reduction. (Singh et al., 2011) Gabapentin is known as 
an anticonvulsant drug classes also have an activity that can 
reduce pain intensity through a mechanism similar to 
Amitriptyline. Gabapentin works by inhibiting the 
hyperactivity especially with blocks Si-Na or prevention of 
central sensitization and increased inhibition which would 
result in a decrease in pain intensity. (Singh et al., 2011; 
Brownlee, 2005) 
 
Conclusion 
 
Amitriptyline was found relatively better in reducing diabetic 
neuropathic pain intensity compared to Gabapentin. 
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